Repligen (RGEN) Stock Forecast & Price Target

$142.58 +0.82 (+0.58%)

(As of 11/22/2024 ET)

Repligen - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 11 Analyst Ratings

Sell
0

Hold
3

Buy
8

Based on 11 Wall Street analysts who have issued ratings for Repligen in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 3 have given a hold rating, and 8 have given a buy rating for RGEN.

Consensus Price Target

$190.25
33.43% Upside

According to the 11 analysts' twelve-month price targets for Repligen, the average price target is $190.25. The highest price target for RGEN is $220.00, while the lowest price target for RGEN is $155.00. The average price target represents a forecasted upside of 33.43% from the current price of $142.58.

Get the Latest News and Ratings for RGEN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Repligen and its competitors.

RGEN Analyst Ratings Over Time

Type	Current Forecast 11/26/23 to 11/25/24	1 Month Ago 10/27/23 to 10/26/24	3 Months Ago 8/28/23 to 8/27/24	1 Year Ago 11/26/22 to 11/26/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)	10 Buy rating(s)
Hold	3 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$190.25	$190.25	$188.38	$189.55
Forecasted Upside	33.43% Upside	40.46% Upside	29.00% Upside	17.16% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

[Money Update] The Calm Before The Storm (Ad)

Right now could be the calm before the storm. Learn how you could protect your money with precious metals like Gold & Silver before it’s too late.

⇒ Send My FREE Guide Today!

RGEN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RGEN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Repligen Stock vs. The Competition

Type	Repligen	Medical Companies	S&P 500
Consensus Rating Score	2.73	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	33.43% Upside	27,006.27% Upside	7.66% Upside
News Sentiment Rating	Positive News See Recent RGEN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/14/2024	Wolfe Research 3 of 5 stars	D. Schenkel Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
9/26/2024	Royal Bank of Canada 4 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$205.00 ➝ $205.00	+37.81%
8/27/2024	Wells Fargo & Company 3 of 5 stars	B. Couillard Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$180.00	+23.26%
8/5/2024	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold
7/31/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$190.00 ➝ $200.00	+18.34%
7/31/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$205.00 ➝ $185.00	+9.86%
“Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad) Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account. Learn these 4 simple steps and protect your savings before it’s too late.
7/30/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$170.00 ➝ $170.00	+9.30%
6/26/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$180.00 ➝ $155.00	+25.86%
6/18/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Nambi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral
2/22/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$165.00 ➝ $207.00	+6.84%
2/15/2024	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$210.00 ➝ $220.00	+6.10%
8/3/2023	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$207.00 ➝ $200.00	+16.73%
1/6/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$230.00 ➝ $200.00	+28.15%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 05:56 AM ET.

RGEN Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Repligen is $190.25, with a high forecast of $220.00 and a low forecast of $155.00.
: 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RGEN shares.
: According to analysts, Repligen's stock has a predicted upside of 33.43% based on their 12-month stock forecasts.
: Repligen has been rated by research analysts at Royal Bank of Canada, Wells Fargo & Company, and Wolfe Research in the past 90 days.
: Analysts like Repligen less than other "medical" companies. The consensus rating score for Repligen is 2.73 while the average consensus rating score for "medical" companies is 2.80. Learn more on how RGEN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW

This page (NASDAQ:RGEN) was last updated on 11/25/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Repligen (RGEN) Stock Forecast & Price Target